Biocodex is a French family-owned com-

pany founded in 1953 to develop and mar-

ket the world’s first probiotic yeast strain,

Saccharomyces boulardii CNCM I-745,

discovered in 1923. Today, Biocodex

develops, manufactures, and distributes

health products in more than 120 coun-

tries. Driven by a profoundly ethical and

responsible approach, the company firmly

believes that, business aside, it is essential

to share knowledge in order to understand

the impact of microbiota on our health.

That conviction underpinned the creation

of the Biocodex Microbiota Foundation in

2017 - a foundation focused on fostering

microbiota-related research and backing

innovative projects geared to improving

human health. An independent, inter-

national, responsible French corporate

foundation.

Independent and open to all, the Biocodex

Microbiota Foundation has one essential

ambition: to support scientific research

and improve our understanding of micro-

biota. In order to achieve its missions, the

Foundation set up a board of directors and

an international scientific committee made

up of independent scientific experts.

International. Belgium, Canada, France,

Mexico, Poland, Portugal, USA and more.

Research into the gut microbiota knows

no borders, and neither does the Biocodex

Microbiota Foundation! Each year, it

rewards dozens of national and interna-

tional research projects. Over the years,

the Biocodex Microbiota Foundation has

brought together a diverse community of

researchers focused on a range of topics

including the gut-brain axis, irritable bowel

syndrome, the role of microbiota in anti-

biotic resistance, microbiota and cancer,

and more. Some 75 projects have been

supported since its creation.

Responsible. In addition to the national

and international grants awarded each

year to support clinical and fundamen-

tal research work, in 2021 the Biocodex

Microbiota Foundation launched the Henri

Boulard Award. It recognizes local initia-

tives that help improve people’s health.

Examples include a contraception aware-

ness campaign in Nigeria designed to

reduce maternal mortality and avoid mis-

use of antibiotics, and a wastewater-based

epidemiology program in Thailand. Like all

the initiatives that have received the Henri

Boulard Award, they have the potential to

transform the daily lives of local popula-

tions and demonstrate the impact of micro-

biota on human health.

Innovation is a core value underpinning the

choices made by the Biocodex Microbiota

Foundation. As you can see, each initiative

and project supported - some of which are

described in this report - will resolutely help

shape the future of medicine.

Enjoy the reading!

President of the Biocodex

Microbiota Foundation

Dr MarieEmmanuelle

Le Guern

7